SBIR Phase II: Efficient Comparative Effective Research Tools In Real Time Environment

SBIR 第二阶段：实时环境中高效的比较有效的研究工具

• 批准号: 1230265
• 负责人: Jeremy Miller
• 金额: $ 50万
• 依托单位: Transmed Systems Inc
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-15 至 2017-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1230265&HistoricalAwards=false
• 关键词: SBIR; Phase; II; Efficient; Comparative

This Small Business Innovation Research (SBIR) Phase II project will focus on the enablement of comparative effectiveness research (CER), evidence based medicine (EBM), and personalized medicine (PM) by researchers utilizing both clinical and complex biomolecular data. The first phase of this grant was focused on a feasibility study working with customers to determine the extent to which the tools we were creating would and could be utilized in practice. This phase is focused on implementation of these tools in real-world health care environments and creating systemic improvements of healthcare by improving tools available for self-evaluation by hospital administrators and clinicians alike. There will be four key objectives accomplished as a result of this proposal. The first is the development of care-improvement algorithms for pediatric ICU patients with sepsis and congenital heart disease. The second will be a reporting engine that mines electronic medical records to create CER reports for patients. The third is an easy-to-use enterprise level reporting engine to check compliance with national standard health care quality metrics and to create new metrics for care improvement. The final objective is to create a personalized medicine reporting system based on next generation sequencing data. The broader impact/commercial potential of this project is significant because it capitalizes on two trends in health care - digitizing patient clinical data and the increasing use of molecular sequencing and microarray data. The commercialization of the technical innovations referenced in this project will enable researchers and clinicians to generate true Comparative Effectiveness Research (CER), Evidence-based precision medicine (EMB) and Personalized Medicine reports (PMR). The ultimate objective of this technology is improving patient outcomes. Leveraging historical patient data in CER to eliminate ineffective therapies from the health care system, coupled with utilizing genetic information to create a more personalized model of health care, will focus precious health care dollars on effective therapies optimized for the individual. Ultimately, this tool will be appealing to every segment of the health care industry including clinicians, researchers, pharmaceutical companies, and insurance companies due to the increases in quality and cost savings that will be created.

该小型企业创新研究（SBIR）第二阶段项目将重点关注研究人员利用临床和复杂的生物分子数据进行比较有效性研究（CER），循证医学（EBM）和个性化医学（PM）。该资助的第一阶段重点是与客户合作进行可行性研究，以确定我们创建的工具在实践中的应用程度。这一阶段的重点是在现实世界的医疗保健环境中实施这些工具，并通过改进医院管理人员和临床医生进行自我评估的工具来实现医疗保健的系统性改进。该提案将实现四个关键目标。第一个是为患有败血症和先天性心脏病的儿科ICU患者开发护理改进算法。第二个将是一个报告引擎，挖掘电子医疗记录，为患者创建CER报告。第三个是一个易于使用的企业级报告引擎，用于检查是否符合国家标准的医疗保健质量指标，并创建新的医疗保健改进指标。最终目标是创建基于下一代测序数据的个性化药物报告系统。该项目更广泛的影响/商业潜力是重要的，因为它利用了医疗保健的两个趋势-数字化患者临床数据和越来越多地使用分子测序和微阵列数据。该项目中引用的技术创新的商业化将使研究人员和临床医生能够生成真正的比较有效性研究（CER），循证精准医学（EMB）和个性化医学报告（PMR）。这项技术的最终目标是改善患者的治疗效果。利用CER中的历史患者数据来消除医疗保健系统中的无效疗法，再加上利用遗传信息来创建更个性化的医疗保健模型，将把宝贵的医疗保健资金集中在为个人优化的有效疗法上。最终，该工具将吸引医疗保健行业的各个部门，包括临床医生，研究人员，制药公司和保险公司，因为它将提高质量和节省成本。